Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian Therapeutic Goods Administration's approval of Kisunla, its novel Alzheimer ...

The decision to register the therapy was supported by data from the Phase III TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 trials.

For the first time in 25 years, a new Alzheimer’s treatment has been approved in Australia. The drug, donanemab, sold as ...

The Therapeutic Goods Administration has approved a new drug tipped to revolutionise the treatment of hundreds of thousands of Australians suffering through early-stage Alzheimer’s disease.

Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, ...

The first ever drug treatment to target the underlying causes of Alzheimer’s disease has become the first alternative ...

Dementia Australia welcomes the Therapeutic Goods Administration (TGA) registration of Kisunla (donanemab), for use in ...

Eli Lilly has received approval in Australia to market its Alzheimer's treatment Kisunla. The pharmaceutical company said Wednesday the Australian Therapeutic Goods Administration granted marketing ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

Hi, it’s Amber in Hong Kong. Across the strait in Taiwan, breakthrough Alzheimer’s drugs are finally becoming available but ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...

Eli Lilly has received approval in Australia to market its Alzheimer's treatment Kisunla. The pharmaceutical company said Wednesday the Australian Therapeutic Goods Administration granted ...